{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Winick N"],"funding":["NCI NIH HHS"],"pagination":["1006-1016"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7749787"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(4)"],"pubmed_abstract":["The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m<sup>2</sup>) vs. 4-h (2 g/m<sup>2</sup>) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = "],"journal":["Leukemia"],"pubmed_title":["Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905."],"pmcid":["PMC7749787"],"funding_grant_id":["U10 CA098543","U10 CA180886","U10 CA180899","U10 CA098413"],"pubmed_authors":["Carroll WL","Larsen E","Shuster J","Carroll A","Borowitz MJ","Paul Bowman W","Devidas M","Camitta BM","Hunger SP","Martin PL","Pullen J","Winick N","Willman C"],"additional_accession":[]},"is_claimable":false,"name":"Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.","description":"The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m<sup>2</sup>) vs. 4-h (2 g/m<sup>2</sup>) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-26T10:10:02.137Z","creation":"2022-02-09T10:54:02.652Z"},"accession":"S-EPMC7749787","cross_references":{"pubmed":["31728054"],"doi":["10.1038/s41375-019-0642-2"]}}